Dr. Ghassan El-Haddad, MD

Dr. Ghassan El-Haddad is the Section Head for the Radionuclide Therapy Program at Moffitt Cancer Center. He is an Associate Member in the Diagnostic Imaging & Interventional Radiology Program and Cancer Physiology Program at Moffitt Cancer Center and an Associate Professor of Radiology and Oncologic Sciences at the University of South Florida. Dr. El-Haddad received his medical degree from the Lebanese University in Beirut, Lebanon. After his internship at SUNY Upstate Medical University, he completed his residency in Nuclear Medicine as well as a fellowship in Nuclear Oncology at the Hospital of the University of Pennsylvania in Philadelphia, PA. Following 2 years of practice at the PET center of the Biomedical Research Foundation of Northwest Louisiana, he completed a Radiology Residency at St Vincent's Medical Center/University of Connecticut in Bridgeport, CT, followed by a fellowship in Vascular and Interventional Radiology at the Hospital of the University of Pennsylvania. Dr. El-Haddad is double board certified by the American Board of Nuclear Medicine (ABNM) and the American Board of Interventional Radiology/Diagnostic Radiology (ABR). He is member of the Board of Directors of the ABNM. He is a founding member of the Society of Interventional Oncology (SIO), an active member of multiple medical societies, including the Radiological Society of North America (RSNA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society of Interventional Radiology (SIR), American Roentgen Ray Society (ARRS), Florida Society of Clinical Oncology (FLASCO), and corresponding member of the European Society of Radiology (ESR) and Cardiovascular Interventional Radiology of Europe (CIRSE). He is a member of the Targeted Radioisotope Therapy Outreach Working Group for the SNMMI, as well as a member of several committees including the Nuclear Medicine/Molecular Imaging Scientific Program Subcommittee for the ARRS. He is an investigator/co-investigator on several phase I/II and III multicenter randomized clinical trials. His research interests include optimization of liver directed therapies to improve outcomes and reduce hepatotoxicity, as well as the development of novel targeted radiopharmaceutical therapies including alpha targeted therapy for metastatic uveal melanoma and neuroendocrine tumors. Dr. El-Haddad's clinical interests are to promote the role of individualized image-guided therapies as part of a multidisciplinary approach to provide the most effective treatment for patients with cancer while maintaining an optimal quality of life. He is specialized in minimally invasive interventional oncology procedures and targeted radionuclide therapy. His expertise includes thermal ablation of primary and metastatic liver and renal tumors (microwave ablation, radiofrequency ablation, cryoablation and nano-knife ablation), embolization of tumors (bland embolization, chemoembolization and radioembolization), lymphangiography and thoracic duct embolization, radio-immunotherapy for lymphoma, alpha targeted therapy for metastatic prostate cancer and peptide receptor radionuclide therapy for metastatic neuroendocrine tumors.